CA-LIVERAMP
8.2.2021 22:03:07 CET | Business Wire | Press release
LiveRamp ® (NYSE: RAMP), the leading data connectivity platform, today announced that it has entered into a definitive agreement to acquire DataFleets , a cloud data platform that enables data silos to be unified without moving data or compromising privacy. This acquisition expands LiveRamp’s data protection capabilities to unlock greater data access and control for its customers. In addition, the deal opens up new use cases as well as new markets for distributed data collaboration through LiveRamp Safe Haven.
With the exponential growth of data, enterprises are constantly evaluating how to best access and leverage data to fuel growth and innovation. Regardless of size, sector or geography, every company is trying to build a data strategy for competitive advantage. However, heightened privacy regulations and security considerations often put limitations on how data can be used or analyzed. Leveraging multiple advanced mathematical privacy technologies, DataFleets offers products that unify distributed data for collaboration and analytics without moving raw data beyond an enterprise’s firewall. Some early and existing privacy tools suffer from a limited set of operations and capabilities that they can handle safely. Now with DataFleets technology, enterprises can access a modern, rich set of data protection tools that can be configured based on each business’s needs. DataFleets’ federated learning technology makes it possible to analyze data across borders and silos in fragmented architectures, as if they were all aggregated to one location. Simply put, DataFleets keeps private data useful, and useful data private.
“This transformative acquisition combines LiveRamp’s deep privacy expertise and widely adopted platform with DataFleets’ game-changing technology, unlocking massive value for the entire ecosystem,” said Anneka Gupta, president and head of products and platforms at LiveRamp. “Together, our combined capabilities will pave the way for the next generation of privacy technology, serving as the foundation for our platform and products, and underscoring our commitment to making it safe and easy for enterprises to use data – wherever it lives.”
With the addition of DataFleets, LiveRamp will further extend its ability to meet evolving marketplace demands by strengthening its differentiated capabilities across four foundational pillars:
- Unlocking Data Access —Proprietary data is available for analytics without requiring the movement of data
- Privacy-Preserving Technology —Identity resolution and collaboration workflows across distributed data sets are supported without compromising privacy or security
- Extended, Global Connectivity —Deeper connections are enabled across data sets formerly siloed by infrastructures, industries and geographies
- Total Control —LiveRamp customers keep continuous control over their data while collaborating and have the ability to choose the right approach and level of data protection to meet their business needs
DataFleets provides Safe Haven customers more flexible options for distributed data collaboration, as well as unlocks privacy-protecting analytics use cases for new industries such as healthcare and financial services. In addition, DataFleets helps LiveRamp’s products and solutions adapt across jurisdictions with privacy designed into their infrastructure layers, empowering customers to comply with evolving privacy regulations around the world.
“With the addition of DataFleets’ technology and their deeply experienced team of industry experts, LiveRamp is now even better positioned to expand our capabilities across geographies and industries,” said Warren Jenson, president and chief financial officer, LiveRamp. “This transaction will support the expansion of LiveRamp’s offerings throughout Europe and in Asia-Pacific and the Latin American market in 2021, and help propel us into new addressable industries like healthcare and financial services, where the combination of DataFleets and LiveRamp together will power high-value use cases.”
David Gilmore, CEO of DataFleets, added, “We are incredibly excited to join the LiveRamp team and continue executing on our shared vision of helping enterprises unify data to unlock maximum value, all while upholding consumer privacy and control. The synergies are strong, and together we can help global enterprises remove barriers to data access and usage to power insights and innovation across their businesses.”
To learn more about LiveRamp’s acquisition of DataFleets, please visit: https://liveramp.com/blog/liveramp-to-acquire-datafleets .
Financial Impact and Closing
The transaction is expected to be completed in LiveRamp’s fiscal fourth quarter. The transaction is not expected to have a material impact on LiveRamp’s fiscal 2021 financial results.
The addition of DataFleets extends LiveRamp’s lead in privacy-preserving identity and data collaboration, driving continued strong growth and value for LiveRamp shareholders.
Third Quarter 2021 Earnings Results
In a separate press release issued today, the Company announced its earnings results for the third quarter of 2021. LiveRamp will host a conference call today at 1:30 pm P.T. to discuss the transaction, as well as its fiscal third quarter 2021 earnings results.
About LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005758/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom